Anamorelin in patients with idiopathic pleuroparenchymal fibroelastosis: A prospective, single-arm, open-label pilot study
Therapeutic Advances in Respiratory Disease · 2026-10 · 20
DOI: 10.1177/17534666261509120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 19.11.2026. Verfasst von Hideki Yasui und 14 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Research Foundation for Clinical Pharmacology.
Abstract (Originalsprache)
Background
Idiopathic pleuroparenchymal fibroelastosis (iPPFE) is a rare, progressive interstitial lung disease with a poor prognosis and no established pharmacological treatment. Cachexia and cachexia-related symptoms are common in patients with iPPFE and are associated with functional decline and poor outcomes.
Objectives
To evaluate the efficacy and safety of anamorelin, an oral ghrelin receptor agonist, in patients with iPPFE.
Design
Prospective interventional study.
Methods
In this single-arm pilot study, patients with iPPFE received oral anamorelin hydrochloride (100 mg once daily) for 8 weeks. The primary endpoint was the change in anorexia- and cachexia-related symptoms assessed using the Anorexia/Cachexia Subscale of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT-A/CS). Exploratory endpoints included changes in body weight, lean body mass, nutritional biomarkers, dyspnoea severity, respiratory-related quality of life (QOL), and handgrip strength. Safety was assessed through clinical and laboratory evaluations.
Results
Nineteen patients were enrolled; 18 received at least one dose of anamorelin, and 15 were included in the efficacy analyses. The median FAACT-A/CS score increased from 26 to 36, with a Hodges-Lehmann estimate of 5.0 (95% confidence interval, 0.5–9.5) ( p = 0.028). Body weight, lean body mass, prealbumin, and transferrin levels increased from baseline. Circulating growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels also increased. Dyspnoea severity decreased, respiratory-related QOL scores increased, and handgrip strength increased. No treatment-related serious adverse events occurred; however, two participants discontinued treatment because of treatment-related adverse events (hepatic enzyme elevation and generalised oedema).
Conclusion
Treatment with anamorelin was associated with improvements in cachexia-related symptoms, body weight, body composition, nutritional biomarkers, respiratory-related QOL, and pharmacodynamic effects on the GH/IGF-1 axis in patients with iPPFE. Given the potential attrition bias, these exploratory findings warrant cautious interpretation and confirmation in randomised controlled trials.
Förderung
- Japan Research Foundation for Clinical Pharmacology
Zitieren
APA
Yasui, H., Inui, N., Inoue, Y., Hozumi, H., Suzuki, Y., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., Ito, H., Masuda, T., Sugiyama, M., Hashimoto, D., Nakamura, Y., & Suda, T. (2026). Anamorelin in patients with idiopathic pleuroparenchymal fibroelastosis: A prospective, single-arm, open-label pilot study. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261509120
Vancouver
Yasui H, Inui N, Inoue Y, Hozumi H, Suzuki Y, Karayama M, et al. Anamorelin in patients with idiopathic pleuroparenchymal fibroelastosis: A prospective, single-arm, open-label pilot study. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261509120
BibTeX
@article{Yasui2026,
author = {Yasui, Hideki and Inui, Naoki and Inoue, Yusuke and Hozumi, Hironao and Suzuki, Yuzo and Karayama, Masato and Furuhashi, Kazuki and Enomoto, Noriyuki and Fujisawa, Tomoyuki and Ito, Hiroyasu and Masuda, Toshihiro and Sugiyama, Misa and Hashimoto, Dai and Nakamura, Yutaro and Suda, Takafumi},
title = {Anamorelin in patients with idiopathic pleuroparenchymal fibroelastosis: A prospective, single-arm, open-label pilot study},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
volume = {20},
doi = {10.1177/17534666261509120}
}
EUVIMED